FDA reviewing first-line Avastin/paclitaxel for advanced breast cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

Genentech has resubmitted a supplemental biologics license application to FDA for Avastin (bevacizumab) in combination with paclitaxel as first-line therapy for locally recurrent or metastatic breast cancer

SOUTH SAN FRANCISCO, California-Genentech has resubmitted a supplemental biologics license application to FDA for Avastin (bevacizumab) in combination with paclitaxel as first-line therapy for locally recurrent or metastatic breast cancer. The resubmission, based on the pivotal phase III E2100 trial, marks the beginning of a 6-month FDA review period. FDA has scheduled an advisory panel review of the application in December. The agency had requested additional information from the trial, including an independent, blinded review of patient scans for progression-free survival, the primary endpoint. Genentech said that "the data from the independent analysis support the original interim results."

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content